Abstract 4384: Targeting of 4-1BB by monoclonal antibody, PF-05082566, enhances T cell function and promotes antitumor activity

• Published in: Cancer research (Chicago, Ill.) Ill.), 2012-04, Vol.72 (8_Supplement), p.4384-4384
• Main Authors: Fisher, Timothy S., Kamperschroer, Cris, Oliphant, Theodore, Love, Victoria A., Lira, Paul D., Doyonnas, Regis, Bergqvist, Simon, Baxi, Sangita, Rohner, Allison, Shen, Amy C., Huang, Chunli, Sokolowski, Sharon, Sharp, Leslie L.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2012-4384

4-1BB (CD137, TNFRSF9) is a costimulatory receptor expressed in an activation induced manner on several subsets of immune cells. Numerous studies of mouse and human T cells indicate that 4-1BB promotes enhanced cellular proliferation, survival, and cytokine production. 4-1BB agonist mAbs have demonstrated efficacy in prophylactic and therapeutic settings in both monotherapy and combination therapy tumor models and have established durable anti-tumor protective T cell memory responses. PF-05082566 is a fully human IgG2 which binds to the extracellular domain of human 4-1BB with high affinity and specificity. In preclinical studies this agonist antibody demonstrated its ability to activate NF-κB and induce downstream cytokine production, promote leukocyte proliferation, and inhibit tumor growth in a human PBMC xenograft tumor model. The mechanism of action and robust anti-tumor efficacy of PF-05082566 support its clinical development for the treatment of a broad spectrum of human malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4384. doi:1538-7445.AM2012-4384